1
|
Bhatta A, Upadhyaya J, Chamlagai D, Dkhar L, Phanrang PT, Rao Kollipara M, Mitra S. Exploring the impact of novel thiazole-pyrazole fused benzo-coumarin derivatives on human serum albumin: Synthesis, photophysical properties, anti-cholinergic activity, and interaction studies. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2024; 308:123669. [PMID: 38006865 DOI: 10.1016/j.saa.2023.123669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 11/18/2023] [Accepted: 11/18/2023] [Indexed: 11/27/2023]
Abstract
Derivatives of thiazole-pyrazole fused benzo-coumarin compounds were successfully synthesized and characterized, followed by a comprehensive spectroscopic investigation on various photophysical properties in different media. The multipronged approach using steady state and time resolved fluorescence spectroscopy pointed out the impact of substitution in the estimated spectroscopic and other physicochemical properties of the systems. Further, the evaluation of anti-acetylcholinesterase (anti-AChE) activity yielded significant insight into the therapeutic potential of the synthesized coumarinyl compounds for the treatment of Alzheimer's disease (AD). The findings revealed a non-competitive mode of inhibition mechanism, with an estimated IC50 value of 67.72 ± 2.00 nM observed for one of the investigated systems as AChE inhibitor. Notably, this value is even lower than that of an FDA-approved AD drug Donepezil (DON), indicating the enhanced potency of the coumarin derivatives in inhibiting AChE. Interestingly, significant diminution in inhibition was observed in presence of human serum albumin (HSA) as evidenced by the relative increase in IC50 value by 8 ∼ 39 % in different cases, which emphasized the role of albumin proteins to control therapeutic efficacies of potential medications. In-depth spectroscopic and in-silico analysis quantified the nature of interactions of the investigated systems with HSA and AChE. Overall, the outcomes of this study provide significant understanding into the biophysical characteristics of novel thiazole-pyrazole fused benzo-coumarin systems, which could aid in the development of new cholinergic agents for the treatment of AD and materials based on coumarin motifs.
Collapse
Affiliation(s)
- Anindita Bhatta
- Department of Chemistry, North-Eastern Hill University, Shillong 793 022, India
| | - Jahnabi Upadhyaya
- Department of Chemistry, North-Eastern Hill University, Shillong 793 022, India
| | - Dipak Chamlagai
- Department of Chemistry, North-Eastern Hill University, Shillong 793 022, India
| | - Lincoln Dkhar
- Department of Chemistry, North-Eastern Hill University, Shillong 793 022, India
| | | | - Mohan Rao Kollipara
- Department of Chemistry, North-Eastern Hill University, Shillong 793 022, India
| | - Sivaprasad Mitra
- Department of Chemistry, North-Eastern Hill University, Shillong 793 022, India.
| |
Collapse
|
2
|
Shang W, Dai W, Yao C, Xu L, Tao X, Su H, Li J, Xie X, Xu Y, Hu M, Xie D, Jiang H, Zhang L, Liu H. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Antiviral Res 2022; 208:105450. [PMID: 36354082 PMCID: PMC9617675 DOI: 10.1016/j.antiviral.2022.105450] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Revised: 10/14/2022] [Accepted: 10/20/2022] [Indexed: 11/26/2022]
Abstract
FB2001 is a drug candidate that targets the main protease of SARS-CoV-2 via covalently binding to cysteine 145. In this study, we evaluated the inhibitory activities of FB2001 against several SARS-CoV-2 variants in vitro and in vivo (in mice), and we also evaluated the histopathological analysis and immunostaining of FB2001 on lung and brain which have been rarely reported. The results showed that FB2001 exhibited potent antiviral efficacy against several current SARS-CoV-2 variants in Vero E6 cells, namely, B.1.1.7 (Alpha): EC50 = 0.39 ± 0.01 μM, EC90 = 0.75 ± 0.01 μM; B.1.351 (Beta): EC50 = 0.28 ± 0.11 μM, EC90 = 0.57 ± 0.21 μM; B.1.617.2 (Delta): EC50 = 0.27 ± 0.05 μM, EC90 = 0.81 ± 0.20 μM; B.1.1.529 (Omicron): EC50 = 0.26 ± 0.06 μM and EC50 = 0.042 ± 0.007 μM (in the presence of a P-glycoprotein inhibitor). FB2001 remained potent against SARS-CoV-2 replication in the presence of high concentrations of human serum, which indicating that human serum had no significant effect on the in vitro inhibitory activity. Additionally, this inhibitor exhibited an additive effect against SARS-CoV-2 when combined with Remdesivir. Furthermore, FB2001 significantly reduced the SARS-CoV-2 copy numbers and titers in the lungs and brains in vivo, and alleviated the pathological symptoms. In addition, FB2001 could alleviated local bleeding, erythrocyte overflow, edema, and inflammatory cell infiltration in brain tissue, and inhibitors reducing viral titers and improving inflammation in the brain have been rarely reported. A physiologically based pharmacokinetic model was established and verified to predict the FB2001 concentration in human lungs. When FB2001 was administered at 200 mg twice a day for 5 days, the observed Ctrough ss in plasma and predicted Ctrough ss of lung total concentration were 0.163 and 2.5 μg/mL, which were approximately 9 and 132-fold higher than the EC50 of 0.019 μg/mL (0.042 μM) against Omicron variant. Taken together, our study suggests that FB2001 is a promising therapeutic agent in COVID-19 treatment and can be combined with remdesivir to achieve improved clinical outcomes. Owing to its good safety and tolerability in healthy human (NCT05197179 and NCT04766931), FB2001 has been approved for Phase II/III clinical trial (NCT05445934).
Collapse
|
3
|
Baruah P, Paul D, Doshi J, Mitra S. Elevated Fibrinogen Level Reduces Therapeutic Efficiency of AD Drugs: Biophysical Insights into the Interaction of FDA-Approved Cholinesterase Inhibitors with Human Fibrinogen. J Phys Chem B 2021; 126:30-43. [PMID: 34964643 DOI: 10.1021/acs.jpcb.1c07495] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Despite being the second most abundant protein in blood plasma, reports on the interaction of drugs with fibrinogen (FIB) are relatively scarce. The effect of FIB on the therapeutic potency of four FDA-approved Alzheimer's disease drugs, namely, tacrine (TAC), donepezil (DON), eserine (ESE), and huperzine (HUP), was investigated through a combination of different in vitro and in silico experiments. The efficiency of the drugs in inhibiting the activity of acetylcholinesterase (AChE) was significantly reduced in the presence of FIB. This effect was even found to be more substantial than that for the most abundant plasma protein, human serum albumin (HSA). For example, the relative change in IC50 for TAC was found to be 65% in 10 μM FIB as opposed to 43% in the presence of 250 μM HSA. The relative trend of modulation in AChE activity showed consistency with the binding efficiency of the drugs and FIB. The sequestration of drugs in FIB, therefore reducing the availability of free drugs in solution, was identified to be the primary cause for the decrease in the AChE inhibition potency. This study aims to establish FIB as a vital component, while considering the therapeutic effectiveness of different newly developed AChE inhibitors.
Collapse
Affiliation(s)
- Prayasee Baruah
- Department of Chemistry, North-Eastern Hill University, Shillong 793022, India
| | - Debojit Paul
- Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati 781039, India
| | - Jitesh Doshi
- BioInsight Solutions (OPC) Pvt. Ltd, Navi Mumbai 410210, India
| | - Sivaprasad Mitra
- Department of Chemistry, North-Eastern Hill University, Shillong 793022, India
| |
Collapse
|
4
|
Zueva I, Lushchekina S, Shulnikova P, Lenina O, Petrov K, Molochkina E, Masson P. α-tocopherol, a slow-binding inhibitor of acetylcholinesterase. Chem Biol Interact 2021; 348:109646. [PMID: 34506764 DOI: 10.1016/j.cbi.2021.109646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 08/03/2021] [Accepted: 09/06/2021] [Indexed: 11/29/2022]
Abstract
Acetylcholinesterase (AChE) is reversibly inhibited by α-tocopherol (α-T). Steady state kinetic analysis shows that α-T is a mixed slow-binding inhibitor of type A of human enzyme (Kci = 0.49 μM; Kui = 1.6 μM) with a residence time of 2 min on target. Molecular dynamics (MD) simulations support this mechanism, and indicate that α-T first forms multiple non-specific interactions with AChE surface near the gorge entrance, then binds to the peripheral side with alkylene chain slowly sliding down the gorge, inducing no significant conformational change. α-T slightly modulates the progressive inhibition of AChE by the cyclic organophosphorus, cresyl saligenylphosphate, accelerating the fast pseudo-first order process of phosphorylation. A moderate accelerating effect of α-T on phosphorylation by paraoxon was also observed after pre-incubation of AChE in the presence of α-T. This accelerating effect of α-T on ex vivo paraoxon-induced diaphragm muscle weakness was also observed. The effect of α-T on AChE phosphylation was interpreted in light of molecular modeling results. From all results it is clear that α-T does not protect AChE against phosphylation by organophosphorus.
Collapse
Affiliation(s)
- Irina Zueva
- Arbuzov Institute of Organic and Physical Chemistry, Federal Research Center "Kazan Scientific Center of the Russian Academy of Sciences", Arbuzov str., 8, Kazan, 420088, Russian Federation
| | - Sofya Lushchekina
- Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Kosygin str 4, Moscow, 119334, Russian Federation
| | - Polina Shulnikova
- Kazan Federal University, Neuropharmacology Laboratory, Kremlevskaya str 18, 480002, Kazan, Russian Federation
| | - Oksana Lenina
- Arbuzov Institute of Organic and Physical Chemistry, Federal Research Center "Kazan Scientific Center of the Russian Academy of Sciences", Arbuzov str., 8, Kazan, 420088, Russian Federation
| | - Konstantin Petrov
- Arbuzov Institute of Organic and Physical Chemistry, Federal Research Center "Kazan Scientific Center of the Russian Academy of Sciences", Arbuzov str., 8, Kazan, 420088, Russian Federation
| | - Elena Molochkina
- Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Kosygin str 4, Moscow, 119334, Russian Federation
| | - Patrick Masson
- Kazan Federal University, Neuropharmacology Laboratory, Kremlevskaya str 18, 480002, Kazan, Russian Federation.
| |
Collapse
|
5
|
Yang J, Li H, Wang X, Zhang C, Feng G, Peng X. Inhibition Mechanism of α-Amylase/α-Glucosidase by Silibinin, Its Synergism with Acarbose, and the Effect of Milk Proteins. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2021; 69:10515-10526. [PMID: 34463509 DOI: 10.1021/acs.jafc.1c01765] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
As a natural flavonolignan, silibinin is reported to possess multiple biological activities, while the inhibitory potential of silibinin on carbohydrate-hydrolyzing enzymes is still unclear. Therefore, in this study, the inhibitory effect and underlying mechanism of silibinin against α-amylase/α-glucosidase were investigated. The results indicated that silibinin showed a strong inhibitory efficiency against α-amylase/α-glucosidase in noncompetitive manners and exhibited synergistic inhibition against α-glucosidase with acarbose. However, interestingly, the inhibitory effect of silibinin was significantly hindered in various milk protein-rich environments, but this phenomenon disappeared after simulated gastrointestinal digestion of milk proteins in vitro. Furthermore, silibinin could combine with the inactive site of α-amylase/α-glucosidase and change the microenvironment and secondary structure of the enzymes, thereby influencing the catalytic efficiency of enzymes. This research suggested that silibinin could be used as a novel carbohydrate-hydrolyzing enzyme inhibitor, and milk beverages rich in silibinin had the potential for further application in antidiabetic dietary or medicine.
Collapse
Affiliation(s)
- Jichen Yang
- School of Life Sciences, Tianjin University, Tianjin 300072, People's Republic of China
| | - Huan Li
- School of Life Sciences, Tianjin University, Tianjin 300072, People's Republic of China
| | - Xiaoli Wang
- School of Life Sciences, Tianjin University, Tianjin 300072, People's Republic of China
| | - Chuanying Zhang
- School of Life Sciences, Tianjin University, Tianjin 300072, People's Republic of China
| | - Guo Feng
- School of Life Sciences, Tianjin University, Tianjin 300072, People's Republic of China
| | - Xin Peng
- School of Life Sciences, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin University, Tianjin 300072, People's Republic of China
- Key Laboratory of Tropical Medicinal Resources Chemistry of Ministry of Education, Hainan Normal University, Haikou, Hainan 571158, People's Republic of China
| |
Collapse
|
6
|
Zhang X, Yu R, Wang H, Zheng R. Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease. Exp Ther Med 2020; 20:1789-1795. [PMID: 32742410 PMCID: PMC7388270 DOI: 10.3892/etm.2020.8872] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 04/06/2020] [Indexed: 12/16/2022] Open
Abstract
The present study aimed to examine the effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease (AD). For this purpose, a total of 126 patients with AD admitted to Luoyang Central Hospital from January, 2018 to December, 2018 were enrolled. Patients were divided into different groups according to the treatment they selected. Patients treated with single-agent donepezil were separated into a monotherapy group (n=56), and patients receiving donepezil plus rivastigmine were placed in the combination group (n=70). Before and after treatment, the cognitive functions, mental behavior and quality of life of the patients in the two groups were respectively evaluated by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (MMSE), the Blessed-Roth Dementia Scale (BRDS) and the QOL-AD. In addition, the serum bradykinin level was detected by enzyme-linked immunosorbent assay. Following treatment, the MMSE score, BRDS, ADAS-Cog and QOL-AD scores were improved compared with those before treatment (P<0.05). However, following treatment, the 4 scores in the combination group were significantly higher than those in the monotherapy group (P<0.05). No significant differences were observed in the incidence of adverse reactions between the 2 groups (P>0.05). Following treatment, the bradykinin level in both groups was significantly decreased (P<0.05), although the decrease in the combination group was more significant than that in the monotherapy group (P<0.05). On the whole, the findings of the present study indicate that rivastigmine hydrogen tartrate used in combination with donepezil hydrochloride relieves the symptoms and improves the quality of life of patients with AD more effectively, which may be related to the reduction of the bradykinin level in these patients.
Collapse
Affiliation(s)
- Xiaohong Zhang
- Department of Rehabilitation, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China
| | - Ronghua Yu
- Department of Rehabilitation, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China
| | - Huilin Wang
- Department of Neurology, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China
| | - Ruifeng Zheng
- Department of Rehabilitation, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China
| |
Collapse
|
7
|
de Freitas Silva M, Tardelli Lima E, Pruccoli L, Castro NG, Guimarães MJR, da Silva FMR, Fonseca Nadur N, de Azevedo LL, Kümmerle AE, Guedes IA, Dardenne LE, Gontijo VS, Tarozzi A, Viegas C. Design, Synthesis and Biological Evaluation of Novel Triazole N-acylhydrazone Hybrids for Alzheimer's Disease. Molecules 2020; 25:E3165. [PMID: 32664425 PMCID: PMC7397262 DOI: 10.3390/molecules25143165] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 07/06/2020] [Accepted: 07/09/2020] [Indexed: 01/29/2023] Open
Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder that involves different pathogenic mechanisms. In this regard, the goal of this study was the design and synthesis of new compounds with multifunctional pharmacological activity by molecular hybridization of structural fragments of curcumin and resveratrol connected by an N-acyl-hydrazone function linked to a 1,4-disubstituted triazole system. Among these hybrid compounds, derivative 3e showed the ability to inhibit acetylcholinesterase activity, the intracellular formation of reactive oxygen species as well as the neurotoxicity elicited by Aβ42 oligomers in neuronal SH-SY5Y cells. In parallel, compound 3e showed a good profile of safety and ADME parameters. Taken together, these results suggest that 3e could be considered a lead compound for the further development of AD therapeutics.
Collapse
Affiliation(s)
- Matheus de Freitas Silva
- Laboratory of Research in Medicinal Chemistry (PeQuiM), Federal University of Alfenas, Jovino Fernandes Sales Avenue, 2600, Alfenas 37130000, MG, Brazil; (E.T.L); (V.S.G.)
| | - Ellen Tardelli Lima
- Laboratory of Research in Medicinal Chemistry (PeQuiM), Federal University of Alfenas, Jovino Fernandes Sales Avenue, 2600, Alfenas 37130000, MG, Brazil; (E.T.L); (V.S.G.)
| | - Letizia Pruccoli
- Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d’Augusto 237, 47921 Rimini, Italy;
| | - Newton G. Castro
- Laboratory of Molecular Pharmacology, Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho, 373, Rio de Janeiro 21941590, RJ, Brazil; (N.G.C.); (M.J.R.G.); (F.M.R.d.S.)
| | - Marcos Jorge R. Guimarães
- Laboratory of Molecular Pharmacology, Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho, 373, Rio de Janeiro 21941590, RJ, Brazil; (N.G.C.); (M.J.R.G.); (F.M.R.d.S.)
| | - Fernanda M. R. da Silva
- Laboratory of Molecular Pharmacology, Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho, 373, Rio de Janeiro 21941590, RJ, Brazil; (N.G.C.); (M.J.R.G.); (F.M.R.d.S.)
| | - Nathalia Fonseca Nadur
- Laboratory of Molecular Diversity and Medicinal Chemistry (LaDMol-QM), Federal Rural University of Rio de Janeiro—UFRRJ, BR-465, Km 7 Seropédica-Rio de Janeiro 23890000, RJ, Brazil; (N.F.N.); (L.L.d.A.); (A.E.K.)
| | - Luciana Luiz de Azevedo
- Laboratory of Molecular Diversity and Medicinal Chemistry (LaDMol-QM), Federal Rural University of Rio de Janeiro—UFRRJ, BR-465, Km 7 Seropédica-Rio de Janeiro 23890000, RJ, Brazil; (N.F.N.); (L.L.d.A.); (A.E.K.)
| | - Arthur Eugen Kümmerle
- Laboratory of Molecular Diversity and Medicinal Chemistry (LaDMol-QM), Federal Rural University of Rio de Janeiro—UFRRJ, BR-465, Km 7 Seropédica-Rio de Janeiro 23890000, RJ, Brazil; (N.F.N.); (L.L.d.A.); (A.E.K.)
| | - Isabella Alvim Guedes
- Grupo de Modelagem Molecular em Sistemas Biológicos (GMMSB), National Laboratory for Scientific Computing—LNCC, Avenida Getúlio Vargas, 333, Petrópolis 25651-076, RJ, Brazil; (I.A.G.); (L.E.D.)
| | - Laurent Emmanuel Dardenne
- Grupo de Modelagem Molecular em Sistemas Biológicos (GMMSB), National Laboratory for Scientific Computing—LNCC, Avenida Getúlio Vargas, 333, Petrópolis 25651-076, RJ, Brazil; (I.A.G.); (L.E.D.)
| | - Vanessa Silva Gontijo
- Laboratory of Research in Medicinal Chemistry (PeQuiM), Federal University of Alfenas, Jovino Fernandes Sales Avenue, 2600, Alfenas 37130000, MG, Brazil; (E.T.L); (V.S.G.)
| | - Andrea Tarozzi
- Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d’Augusto 237, 47921 Rimini, Italy;
| | - Claudio Viegas
- Laboratory of Research in Medicinal Chemistry (PeQuiM), Federal University of Alfenas, Jovino Fernandes Sales Avenue, 2600, Alfenas 37130000, MG, Brazil; (E.T.L); (V.S.G.)
| |
Collapse
|
8
|
Rohman MA, Baruah P, Bhatta A, Mitra S. Deciphering the interactions of substituted chromones possessing acetylcholinesterase inhibition activity in human serum albumin matrix. J Mol Liq 2019. [DOI: 10.1016/j.molliq.2019.111210] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Baruah P, Rohman MA, Yesylevskyy SO, Mitra S. Therapeutic potency of substituted chromones as Alzheimer's drug: Elucidation of acetylcholinesterase inhibitory activity through spectroscopic and molecular modelling investigation. BIOIMPACTS : BI 2019; 9:79-88. [PMID: 31334039 PMCID: PMC6637216 DOI: 10.15171/bi.2019.11] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Revised: 11/13/2018] [Accepted: 11/17/2018] [Indexed: 11/09/2022]
Abstract
Introduction: Documentation on the potency of chromones as acetylcholinesterase (AChE) antagonists has paved the way for the design and usage of new chromone analogues as inhibitors of AChE modelled on the hypothesis based on cholinergic pathway of Alzheimer's disease (AD). Here, 2 minimally substituted chromones, namely 3-cyanochromone (CyC) and 7-amino-3- methylchromone (AMC), were checked for their AChE inhibition efficacies and plasma protein modulation. Methods: Colorimetric enzymatic assay as well as fluorescence measurements were performed for obtaining the experimental results, which were further corroborated by molecular docking and simulation studies. Results: The investigated systems exhibited strong inhibition activities against AChE, with CyC (IC50= 85.12 ± 6.70 nM) acting as better inhibitor than AMC (IC50 = 103.09 ± 11.90 nM) and both having IC50 values in the range of FDA approved cholinergic drug Donepezil (IC50 = 74.13 ± 8.30 nM). Non-competitive inhibition was observed in both the cases with the inhibitors binding near the peripheral anionic site (PAS) of the enzyme. Having one planar nitrile group in CyC as compared to sp3 hybridised substituents in AMC facilitated stacking interactions in the former, accounting for its higher inhibitory efficacy. A significant decrease in the inhibition potency of CyC (~32%) was noted in comparison with AMC (~5%) when the experiments were performed in presence of human serum albumin (HSA) instead of pure aqueous buffer. Conclusion: This comparative study affirms the importance of meticulous substitution in the chromone scaffold to promote maximum inhibition potency, while considering their usage as AD drugs.
Collapse
Affiliation(s)
- Prayasee Baruah
- Centre for Advanced Studies in Chemistry, North-Eastern Hill University, Shillong – 793 022, India
| | - Mostofa Ataur Rohman
- Centre for Advanced Studies in Chemistry, North-Eastern Hill University, Shillong – 793 022, India
| | - Semen O. Yesylevskyy
- Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine, Prospect Nauky 46, 03028 Kyiv, Ukraine
| | - Sivaprasad Mitra
- Centre for Advanced Studies in Chemistry, North-Eastern Hill University, Shillong – 793 022, India
| |
Collapse
|
10
|
Rohman MA, Baruah P, Bhattacharjee D, Myrboh B, Mitra S. Fluorescence solvatochromism and modulated anticholinergic activity of novel coumarin compounds sequestered in human serum albumin nanocavities. NEW J CHEM 2019. [DOI: 10.1039/c9nj03293b] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The antagonistic effect of the HSA matrix towards the acetylcholinesterase inhibition potencies of novel coumarin compounds is probed by multi-spectroscopic techniques.
Collapse
Affiliation(s)
- Mostofa Ataur Rohman
- Centre for Advanced Studies in Chemistry
- North-Eastern Hill University
- Shillong 793 022
- India
| | - Prayasee Baruah
- Centre for Advanced Studies in Chemistry
- North-Eastern Hill University
- Shillong 793 022
- India
| | | | - B. Myrboh
- Centre for Advanced Studies in Chemistry
- North-Eastern Hill University
- Shillong 793 022
- India
| | - Sivaprasad Mitra
- Centre for Advanced Studies in Chemistry
- North-Eastern Hill University
- Shillong 793 022
- India
| |
Collapse
|
11
|
Baruah P, Basumatary G, Yesylevskyy SO, Aguan K, Bez G, Mitra S. Novel coumarin derivatives as potent acetylcholinesterase inhibitors: insight into efficacy, mode and site of inhibition. J Biomol Struct Dyn 2018; 37:1750-1765. [DOI: 10.1080/07391102.2018.1465853] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Prayasee Baruah
- Centre for Advanced Studies in Chemistry and Department of Biotechnology & Bioinformatics, North-Eastern Hill University , Shillong, India
| | - Grace Basumatary
- Centre for Advanced Studies in Chemistry and Department of Biotechnology & Bioinformatics, North-Eastern Hill University , Shillong, India
| | - Semen O. Yesylevskyy
- Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine , Kyiv, Ukraine
| | - Kripamoy Aguan
- Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine , Kyiv, Ukraine
| | - Ghanashyam Bez
- Centre for Advanced Studies in Chemistry and Department of Biotechnology & Bioinformatics, North-Eastern Hill University , Shillong, India
| | - Sivaprasad Mitra
- Centre for Advanced Studies in Chemistry and Department of Biotechnology & Bioinformatics, North-Eastern Hill University , Shillong, India
| |
Collapse
|
12
|
C-547, a 6-methyluracil derivative with long-lasting binding and rebinding on acetylcholinesterase: Pharmacokinetic and pharmacodynamic studies. Neuropharmacology 2018; 131:304-315. [DOI: 10.1016/j.neuropharm.2017.12.034] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Revised: 12/07/2017] [Accepted: 12/19/2017] [Indexed: 01/09/2023]
|
13
|
Islam MM, Rohman MA, Gurung AB, Bhattacharjee A, Aguan K, Mitra S. Correlation of cholinergic drug induced quenching of acetylcholinesterase bound thioflavin-T fluorescence with their inhibition activity. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2018; 189:250-257. [PMID: 28822269 DOI: 10.1016/j.saa.2017.08.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Revised: 07/17/2017] [Accepted: 08/02/2017] [Indexed: 06/07/2023]
Abstract
The development of new acetylcholinesterase inhibitors (AChEIs) and subsequent assay of their inhibition efficiency is considered to be a key step for AD treatment. The fluorescence intensity of thioflavin-T (ThT) bound in the active site of acetylcholinesterase (AChE) quenches substantially in presence of standard AChEI drugs due to the dynamic replacement of the fluorophore from the AChE active site as confirmed from steady state emission as well as time-resolved fluorescence anisotropy measurement and molecular dynamics simulation in conjunction with docking calculation. The parametrized % quenching data for individual system shows excellent correlation with enzyme inhibition activity measured independently by standard Ellman AChE assay method in a high throughput plate reader system. The results are encouraging towards design of a fluorescence intensity based AChE inhibition assay method and may provide a better toolset to rapidly evaluate as well as develop newer AChE-inhibitors for AD treatment.
Collapse
Affiliation(s)
- Mullah Muhaiminul Islam
- Center for Advanced Studies in Chemistry, North-Eastern Hill University, Shillong 793 022, India
| | - Mostofa Ataur Rohman
- Center for Advanced Studies in Chemistry, North-Eastern Hill University, Shillong 793 022, India
| | - Arun Bahadur Gurung
- Department of Biotechnology & Bio-informatics, North-Eastern Hill University, Shillong 793 022, India
| | - Atanu Bhattacharjee
- Department of Biotechnology & Bio-informatics, North-Eastern Hill University, Shillong 793 022, India
| | - Kripamoy Aguan
- Department of Biotechnology & Bio-informatics, North-Eastern Hill University, Shillong 793 022, India
| | - Sivaprasad Mitra
- Center for Advanced Studies in Chemistry, North-Eastern Hill University, Shillong 793 022, India.
| |
Collapse
|